Caeregen Therapeutics and Wacker Biotech Announce Collaboration Agreement to Produce the Regenerative Medicine Clinical Candidate CTR-107 (Noregen) for Retinal Diseases finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Caeregen Therapeutics and Wacker Biotech Announce Collaboration Agreement to Produce the Regenerative Medicine Clinical Candidate CTR-107 (Noregen™) for Retinal Diseases streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
How Wacker Chemie is using data to transform a traditional chemical company into a digital one
Read later
Audio version
Summary:
“You can t digitalise a chemical product but you can provide services around the production of that product that makes you more sustainable, efficient and more intelligent,” says the Wacker Chemie’s CIO
(Image sourced via Wacker Chemie )
Founded in 1914, Munich-based Wacker Chemie AG is a €5 billion chemicals firm with operations around the world that provides specialty chemical products for many applications and everyday items, from cosmetics to solar cells to paint colours. Its portfolio includes more than 3,200 products, including numerous silicone products and polymeric binders. Though publicly listed, the company is still majority-owned by the Wacker family, and is classed in German company terms as a mid-size corporation, though at the upper end of that.